{"nctId":"NCT01076075","briefTitle":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","startDateStruct":{"date":"2010-06-03","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":427,"armGroups":[{"label":"placebo/pioglitazone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: placebo to Sitagliptin","Drug: Comparator: pioglitazone","Drug: Glimepiride or gliclazide","Drug: Metformin","Drug: Pioglitazone rescue therapy"]},{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin phosphate","Drug: Comparator: placebo to pioglitazone","Drug: Glimepiride or gliclazide","Drug: Metformin","Drug: Pioglitazone rescue therapy"]}],"interventions":[{"name":"Sitagliptin phosphate","otherNames":["Januvia"]},{"name":"Comparator: placebo to pioglitazone","otherNames":[]},{"name":"Comparator: placebo to Sitagliptin","otherNames":[]},{"name":"Comparator: pioglitazone","otherNames":["Actos;"]},{"name":"Glimepiride or gliclazide","otherNames":[]},{"name":"Metformin","otherNames":[]},{"name":"Pioglitazone rescue therapy","otherNames":["Actos"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes mellitus\n* Hemoglobin A1C of ≥7.5% and ≤10.5%\n* Currently taking a stable dose of metformin (at least 1500 mg/day) and either glimepiride (at least 2 mg/day) or gliclazide (at least 50% of maximum registered dose) for at least 10 weeks prior to study start\n* Male, or a female who is highly unlikely to conceive\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus or ketoacidosis\n* Taking a dipeptidyl peptidase-4 (DPP-4) inhibitor (such as sitagliptin) or a glucagon-like peptide-1 (GLP-1) mimetic (such as exenatide or liraglutide) or required insulin therapy within 12 weeks prior to study start\n* On a weight loss program not in the maintenance phase or on a weight loss medication\n* History of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer\n* HIV positive\n* Pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1C (%) at Week 24","description":"Change from baseline reflects the Week 24 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":"0.82"},{"groupId":"OG001","value":"-0.16","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Post-Meal Glucose at Week 24","description":"Change from baseline reflects the Week 24 value minus the baseline value. Two-hour post-meal glucose was measured following a standard meal.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.8","spread":"60.8"},{"groupId":"OG001","value":"-3.3","spread":"67.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 24","description":"Change from baseline reflects the Week 24 value minus the baseline value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.2","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Discontinuing Study Drug Due to An Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":210},"commonTop":["Hypoglcaemia","Upper respiratory tract infection"]}}}